Clinical Trial Update: Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation

View source ↗

Summary

Post-marketing surveillance study update on long-term use of Prazaxa in patients with nonvalvular atrial fibrillation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Prazaxa (null)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Atrial Fibrillation | Status: COMPLETED | Results posted: 2018-01-30